How does REC N's pe Ratio compare to its peers?

REC N is good value based on its Price-To-Earnings Ratio (26.3x) compared to the peer average (32.7x).

How does REC N's pe Ratio compare vs other companies in the Global Pharmaceuticals Industry?

REC N is expensive based on its Price-To-Earnings Ratio (26.3x) compared to the Global Pharmaceuticals industry average (22.4x).

What is REC N's pe Ratio compared to its Fair pe Ratio? This is the expected pe Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate REC N's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of REC N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

REC N (MX$1188.76) is trading below our estimate of [[fair value]] (MX$1207.58)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Recordati Industria Chimica e Farmaceutica (BMV:REC N) - Stock Price, News & Analysis

REC N Stock Overview

Engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. More details

REC N fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	4/6
Financial Health	4/6
Dividends	4/6

Rewards

Trading at 1.6% below our estimate of its fair value

Earnings are forecast to grow 11.88% per year

Earnings have grown 1.3% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Recordati Industria Chimica e Farmaceutica S.p.A. Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$22.6b

Torrent Pharmaceuticals

BSE:500420

₹1.0t

Dr. Reddy's Laboratories

BSE:500124

₹943.8b

Mankind Pharma

NSEI:MANKIND

₹955.6b

Price History & Performance

Summary of share price highs, lows and changes for Recordati Industria Chimica e Farmaceutica
Historical stock prices
Current Share Price	€1,188.76
52 Week High	€1,188.76
52 Week Low	€1,188.76
Beta	0.47
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	REC N	MX Pharmaceuticals	MX Market
7D	0%	-0.07%	1.1%
1Y	n/a	-21.5%	-7.7%

Return vs Industry: Insufficient data to determine how REC N performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how REC N performed against the MX Market.

Price Volatility

Is REC N's price volatile compared to industry and market?
REC N volatility
REC N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.8%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	7.3%
10% least volatile stocks in MX Market	2.7%

Stable Share Price: REC N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine REC N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1926	4,455	Rob Koremans	www.recordati.com

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. It operates through Specialty and Primary Care and Rare Diseases segments. The company’s product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS for the treatment of cystine crystal deposits in the cornea.

Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary

How do Recordati Industria Chimica e Farmaceutica's earnings and revenue compare to its market cap?
REC N fundamental statistics
Market cap	Mex$240.58b
Earnings (TTM)	Mex$9.15b
Revenue (TTM)	Mex$51.45b

26.3x

P/E Ratio

4.7x

P/S Ratio

Is REC N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REC N income statement (TTM)
Revenue	€2.34b
Cost of Revenue	€703.80m
Gross Profit	€1.64b
Other Expenses	€1.22b
Earnings	€416.50m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Mar 18, 2025

Earnings per share (EPS)	2.04
Gross Margin	69.94%
Net Profit Margin	17.79%
Debt/Equity Ratio	83.8%

How did REC N perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

60%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/09 19:20
End of Day Share Price	2025/02/19 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Paola Saglietti	Banca Akros S.p.A. (ESN)
Charles Pitman-King	Barclays
Vincent Meunier	BNP Paribas Exane